Jessica Tassan
Stock Analyst at Piper Sandler
(0.59)
# 4,187
Out of 4,634 analysts
226
Total ratings
41.8%
Success rate
-2.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRVA Privia Health Group | Maintained: Buy | $36 | $22.37 | +60.93% | 12 | Aug 7, 2026 | |
| DOCS Doximity | Reiterated: Buy | $42 → $47 | $25.63 | +83.38% | 14 | Aug 7, 2026 | |
| OMCL Omnicell | Reiterated: Buy | $49 → $45 | $37.31 | +20.61% | 22 | Aug 3, 2026 | |
| HUM Humana | Upgraded: Buy | $254 → $463 | $385.70 | +20.04% | 8 | Jul 30, 2026 | |
| OSCR Oscar Health | Rated: Buy | $25 → $36 | $27.67 | +30.10% | 9 | Jul 28, 2026 | |
| UNH UnitedHealth Group | Maintained: Buy | $420 → $475 | $408.74 | +16.21% | 20 | Jul 15, 2026 | |
| CTEV Claritev | Maintained: Buy | $90 → $61 | $34.07 | +79.04% | 10 | Jun 3, 2026 | |
| PHR Phreesia | Downgraded: Hold | $34 → $12 | $12.44 | -3.54% | 16 | May 28, 2026 | |
| HCAT Health Catalyst | Reiterated: Hold | $4 → $2 | $1.73 | +15.94% | 17 | May 12, 2026 | |
| HNGE Hinge Health | Maintained: Buy | $60 → $95 | $91.57 | +3.75% | 6 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $101 → $99 | $95.67 | +3.48% | 11 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $374 → $370 | $278.40 | +32.90% | 6 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $13.78 | +117.71% | 14 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $9 | $7.08 | +27.12% | 22 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.93 | +358.02% | 22 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $8 | $13.58 | n/a | 13 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $13 → $10 | $5.00 | n/a | 4 | Jan 17, 2024 |
Privia Health Group
Aug 7, 2026
Maintained: Buy
Price Target: $36
Current: $22.37
Upside: +60.93%
Doximity
Aug 7, 2026
Reiterated: Buy
Price Target: $42 → $47
Current: $25.63
Upside: +83.38%
Omnicell
Aug 3, 2026
Reiterated: Buy
Price Target: $49 → $45
Current: $37.31
Upside: +20.61%
Humana
Jul 30, 2026
Upgraded: Buy
Price Target: $254 → $463
Current: $385.70
Upside: +20.04%
Oscar Health
Jul 28, 2026
Rated: Buy
Price Target: $25 → $36
Current: $27.67
Upside: +30.10%
UnitedHealth Group
Jul 15, 2026
Maintained: Buy
Price Target: $420 → $475
Current: $408.74
Upside: +16.21%
Claritev
Jun 3, 2026
Maintained: Buy
Price Target: $90 → $61
Current: $34.07
Upside: +79.04%
Phreesia
May 28, 2026
Downgraded: Hold
Price Target: $34 → $12
Current: $12.44
Upside: -3.54%
Health Catalyst
May 12, 2026
Reiterated: Hold
Price Target: $4 → $2
Current: $1.73
Upside: +15.94%
Hinge Health
May 6, 2026
Maintained: Buy
Price Target: $60 → $95
Current: $91.57
Upside: +3.75%
Mar 31, 2026
Rated: Buy
Price Target: $101 → $99
Current: $95.67
Upside: +3.48%
Mar 3, 2026
Reiterated: Buy
Price Target: $374 → $370
Current: $278.40
Upside: +32.90%
Mar 2, 2026
Reiterated: Buy
Price Target: $30
Current: $13.78
Upside: +117.71%
Feb 26, 2026
Reiterated: Buy
Price Target: $12 → $9
Current: $7.08
Upside: +27.12%
Sep 5, 2025
Reiterated: Buy
Price Target: $18
Current: $3.93
Upside: +358.02%
May 23, 2025
Reiterated: Hold
Price Target: $10 → $8
Current: $13.58
Upside: n/a
Jan 17, 2024
Maintained: Hold
Price Target: $13 → $10
Current: $5.00
Upside: n/a